DRREDDY
Dr. Reddy's Laboratories Limited
NSELast Traded Price
₹1303.5
1 (0.08%)
Open
₹1318.8
High
₹1328.6
Low
₹1297.5
Prev Close
₹1319
Industry
Pharmaceuticals
Market Cap
110174.72 Cr
Filing History
Recent corporate announcements and filings for DRREDDY
Routine
Neutral
2026-05-30 13:09
Dr. Reddy's Laboratories Ltd. has informed about the filing of its Annual Report in Form 20-F, containing annual consolidated financial statements for the fiscal year ended March 31, 2026, with the United States Securities and Exchange Commission on May 30, 2026. The report is also available on the company's website.
Business Update
Positive
2026-05-28 15:33
Dr. Reddy's Laboratories announced it will ring the Closing Bell at the New York Stock Exchange on May 29, 2026, to celebrate 25 years of its NYSE listing. The company, which first listed in April 2001, was the first pharmaceutical company in Asia, outside Japan, to be listed on the NYSE. Chairman Satish Reddy highlighted the event as a reaffirmation of the company's commitment to global governance, transparency, and innovation.
Business Update
Neutral
2026-05-18 21:26
Dr. Reddy's Laboratories Ltd. announced the filing and availability of the transcript for its earnings call conducted on May 12, 2026, pertaining to the quarter and financial year ended March 31, 2026. The transcript is available on the company's website.
Business Update
Positive
2026-05-16 00:29
Dr. Reddy's Laboratories launched its generic Semaglutide Injection in Canada on May 15, 2026. The company is the first to receive Health Canada approval for this generic, making Canada the first G7 country to grant market authorization. This product is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus, aiming to improve glycemic control. Dr. Reddy's emphasizes its commitment to providing advanced, high-quality, and affordable GLP-1 therapies and plans to expand access across multiple global markets.
Business Update
Neutral
2026-05-12 23:31
Dr. Reddy's Laboratories Ltd. informed about the availability of the audio recording of its earnings call for the quarter ended March 31, 2026. The call was conducted on May 12, 2026, and the recording is accessible via the provided weblink, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Financials
Negative
2026-05-12 18:52
Dr. Reddy's Laboratories reported consolidated Q4 FY26 results with Revenue at ₹7,516.2 Cr vs ₹8,506.0 Cr (▼11.63% YoY), Operating Profit (EBIT proxy) at ₹132.5 Cr vs ₹1,764.7 Cr (▼92.49% YoY), and PAT at ₹220.1 Cr vs ₹1,593.9 Cr (▼86.19% YoY). Operating Profit Margin contracted significantly to 1.76% from 20.74% (▼1898bps). The board also recommended a final dividend of INR 8/- per equity share for FY 2025-26 and approved various governance matters including director and auditor appointments.
Routine
Neutral
2026-05-12 18:52
New Filing detected. See link for details.
Governance
Neutral
2026-05-12 18:51
The Board of Directors of Dr. Reddy's Laboratories Ltd., in its meeting on May 12, 2026, approved the re-appointment of Dr. K P Krishnan as an Independent Director for a second term of five years and the appointment of Mr. Srikanth Velamakanni as an Independent Director for a five-year term. The Board also approved the appointment of M/s Deloitte Haskins & Sells, LLP as Statutory Auditors for five years, re-appointed M/s Sagar & Associates as Cost Auditors for FY 2026-27, and elevated Mr. Sandeep Khandelwal as a Senior Management Personnel.
Routine
Neutral
2026-05-12 17:13
New Filing detected. See link for details.
Governance
Neutral
2026-05-12 17:13
Dr. Reddy's Laboratories Ltd. announced the outcome of its Board Meeting held on May 12, 2026. Key approvals include the re-appointment of Dr. K P Krishnan as an Independent Director for a second term of five years (Jan 7, 2027 to Jan 6, 2032), and the appointment of Mr. Srikanth Velamakanni as an Independent Director for five years (July 1, 2026 to June 30, 2031). M/s Deloitte Haskins & Sells, LLP was appointed as Statutory Auditors for five years, and M/s Sagar & Associates were re-appointed as Cost Auditors for FY 2026-27. Additionally, Mr. Sandeep Khandelwal was elevated to Senior Management Personnel.
Financials
Negative
2026-05-12 16:50
Consolidated Revenue ₹75,162Mn vs ₹85,060Mn (▼11.6% YoY), Operating Profit (Results from operating activities) ₹1,325Mn vs ₹17,647Mn (▼92.5% YoY), PAT attributable to equity holders ₹2,201Mn vs ₹15,939Mn (▼86.2% YoY). Operating Profit Margin 1.76% vs 20.75% (▼1899bps). The Board recommended a final dividend of INR 8/- per equity share for FY2025-26, subject to shareholder approval.
Business Update
Neutral
2026-05-11 21:53
Dr. Reddy's management will participate in investor meetings. These include an in-person group meet with HSBC in Mumbai on May 14-15, 2026, and another in-person group meet with Bank of America in Singapore on May 18-19, 2026. The schedule is subject to change.
Ownership
Positive
2026-05-11 19:31
Dr. Reddy's Laboratories Ltd. announced that its Nomination, Governance and Compensation Committee approved the grant of 8,16,119 Indian Stock Options and 3,76,115 American Depository Receipts (ADRs) Stock Options to eligible employees on May 11, 2026. The options have an exercise price of Rs. 1,293.90/- per share and will vest 100% at the end of 3 years.
Business Update
Positive
2026-04-29 09:13
Dr. Reddy's Laboratories Ltd. has received a Notice of Compliance (i.e., an approval) from Health Canada for its Abbreviated New Drug Submission (ANDS) of Semaglutide Injection. This makes Dr. Reddy's the first company to receive marketing authorization for generic Semaglutide Injection in Canada, enabling commercialization, sale, and distribution of the product for Type 2 diabetes patients.
Financials
Neutral
2026-04-24 14:41
Dr. Reddy's Laboratories Ltd. will release its Q4 and full year FY26 results on Tuesday, May 12th, 2026, after the Board Meeting. An earnings call to discuss the financial performance is scheduled for 19:30 PM IST / 10:00 AM ET on the same day.
Business Update
Neutral
2026-04-24 09:36
Dr. Reddy's Laboratories clarified a news report stating they are awaiting approval for Semaglutide Injection from Health Canada. The company confirmed receipt of Drug Identification Numbers (DINs) on April 22, 2026, but is still awaiting final Notice of Compliance, reiterating engagement with regulatory authorities.
Business Update
Neutral
2026-04-24 09:14
Dr. Reddy's confirmed it is still awaiting final approval ('Notice of Compliance') for its Semaglutide Injection from Health Canada. However, the company received 'Drug Identification Numbers (DINs)' for the product on April 22, 2026, indicating progress in the regulatory review process.
Routine
Neutral
2026-04-23 13:50
New Filing detected. See link for details.
Governance
Positive
2026-04-16 15:45
Dr. Reddy's Laboratories Ltd. announced on April 16, 2026, a Board Meeting to consider recommending a final dividend for the financial year 2025-26.
Business Update
Negative
2026-04-14 21:19
CRITICAL RED FLAG DETECTED
Dr. Reddy's Laboratories LLC, Russia, a subsidiary, received a final tax penalty of RUB 9.27 million (INR 11.40 million) on April 13, 2026, from the Russian Tax Authority for VAT re-classification. The company states this penalty has no material financial impact.
Routine
Neutral
2026-04-08 16:03
Dr. Reddy's Laboratories Ltd. filed a certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. It confirms the processing, dematerialisation, and cancellation of physical share certificates by Bigshare Services Private Limited.
Business Update
Neutral
2026-04-07 19:37
Dr. Reddy's Laboratories Limited announced on April 7, 2026, the sale of its wholly-owned subsidiary, Svaas Wellness Limited, for INR 2.23 Cr. Svaas Wellness's FY25 turnover was approximately 0.09% of Dr. Reddy's consolidated turnover.
Ownership
Neutral
2026-03-26 14:34
Dr. Reddy's Laboratories Ltd. allotted 3,675 equity shares of Re.1/- each on March 26, 2026, to eligible employees upon exercise of stock options under its ESOP Scheme, 2007.
Governance
Neutral
2026-03-24 19:27
Dr. Reddy's Laboratories Limited has adopted an amended 'Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information' as approved by the Board of Directors on March 24, 2026, in compliance with SEBI PIT Regulations, 2015.
Governance
Neutral
2026-03-23 17:38
Dr. Reddy's Laboratories will hold a Board meeting on May 12, 2026, to approve Audited Standalone and Consolidated Financial Results for the quarter and financial year ending March 31, 2026. The trading window will be closed from March 25 to May 14, 2026.
Business Update
Positive
2026-03-21 14:01
Dr. Reddy's Laboratories launched Obeda®, India's first DCGI-approved generic Semaglutide injection for Type 2 Diabetes. This marks their Day-1 entry into the GLP-1 receptor agonists therapy space, developed in-house, and priced at INR 4,200 per month.
Business Update
Negative
2026-03-17 17:25
CRITICAL RED FLAG DETECTED
Dr. Reddy's received three GST orders on March 16, 2026, demanding tax, interest, and penalties totaling approx. ₹2.2 Cr for FY 2019-2022. The company states there's no material financial impact and plans to appeal these orders.
Business Update
Negative
2026-03-13 18:41
Dr. Reddy's SA's partner Immutep is discontinuing the TACTI-004 Phase III trial for Eftilagimod Alfa in non-small cell lung cancer due to futility analysis. Dr. Reddy's SA had an exclusive licensing agreement for the drug and made an upfront payment.
Routine
Neutral
2026-03-12 12:28
Dr. Reddy's Laboratories Ltd. allotted 10,275 equity shares of Re.1/- each to eligible employees on March 12, 2026, upon exercise of Stock Options under the company's ESOP schemes.
Business Update
Positive
2026-03-10 23:54
Dr. Reddy's announced that the Delhi High Court, in a judgment dated March 09, 2026, upheld the permission for the company to manufacture Semaglutide in India and export it to countries where Novo Nordisk has no patent. The court refused an interim injunction on Semaglutide products.
Governance
Neutral
2026-03-10 20:01
Dr. Reddy's Laboratories announced the elevation of Mr. M S Madhu Sundar to Global Head of Quality and PV, effective April 1, 2026. Additionally, other Senior Management Personnel had their roles revised, including Mr. M V Ramana becoming CEO Global Generics and Mr. Sanjay Sharma becoming Chief Operating Officer.
Business Update
Positive
2026-03-06 17:16
Dr. Reddy's Laboratories announced that the U.S. Department of Justice (DOJ) has closed its inquiry under the Foreign Corrupt Practices Act (FCPA) regarding allegations of improper payments. The DOJ has not recommended any enforcement action against the company, following a similar conclusion by the SEC.
Business Update
Positive
2026-03-05 16:05
Dr. Reddy's received the USFDA's Establishment Inspection Report for its Srikakulam facility, classifying the outcome as 'Voluntary Action Indicated (VAI)'. The inspection is officially closed as of March 04, 2026.
Business Update
Neutral
2026-02-27 12:33
Dr. Reddy's management will participate in investor meetings with Ambit Capital on March 4, 2026 (in-person) and Goldman Sachs on March 5, 2026 (virtual) to engage with institutional investors.
Business Update
Positive
2026-02-24 17:33
Dr. Reddy's received a letter from the SEC on February 23, 2026, stating it has concluded its investigation into alleged improper payments in Ukraine (initially disclosed Nov 2020) and does not intend to recommend enforcement action against the company at this time.
Business Update
Positive
2026-02-18 19:46
Dr. Reddy's acquired Progynova® and Cyclo-Progynova® trademarks and assets for India from Mercury Pharma Group Limited for USD 32.15 million. This strengthens its gynecology portfolio and marks a strategic entry into the Hormone Replacement Therapy segment.
Routine
Neutral
2026-02-17 15:59
Dr. Reddy's Laboratories Ltd. allotted 12,665 equity shares of Re.1/- each to eligible employees on February 17, 2026, upon exercise of stock options under its Dr. Reddy's Employees Stock Options Scheme, 2002 and Dr. Reddy's Employees ADR Stock Options Scheme, 2007.
Business Update
Neutral
2026-02-12 15:49
Dr. Reddy's Laboratories Ltd. management will participate in an in-person Group Meet with Kotak Institutional Equities in Mumbai on February 23, 2026, as part of an analyst/institutional investor meeting.
Governance
Negative
2026-02-09 18:17
CRITICAL RED FLAG DETECTED
Mr. Sushrut Kulkarni has resigned from his position as Global Head of IPDO and Senior Management Personnel of Dr. Reddy's Laboratories Limited, effective May 8, 2026, to explore external opportunities.